Quantcast
Last updated on April 25, 2014 at 1:22 EDT

Latest XTL Biopharmaceuticals Ltd. Stories

2014-04-02 16:31:44

HERZLIYA, Israel, April 2, 2014 /PRNewswire/ -- XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTL) ("XTL" or the "Company"), a clinical-stage biopharmaceutical company focused on the acquisition, development and commercialization of pharmaceutical products for the treatment of unmet clinical needs, today announced its financial and operational results for the year ended December 31, 2013. Company Highlights: -- Reorganized and strengthened management team -- Appointed Josh...

2014-03-25 08:29:48

HERZLIYA, Israel, March 25, 2014 /PRNewswire/ -- XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTL) ("XTL" or the "Company"), a clinical-stage biopharmaceutical company focused on the acquisition, development and commercialization of pharmaceutical products for the treatment of unmet clinical needs, today announced the appointment of Daniel J. Wallace, MD and Murray Urowitz, MD, two experts in rheumatology, as consultants for the planned Phase II trial for the Company's hCDR1...

2014-01-08 08:28:37

HERZLIYA, Israel, January 8, 2014 /PRNewswire/ -- XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB) (TASE: XTL) ("XTL" or the "Company"), a clinical-stage biopharmaceutical company focused on the acquisition, development and commercialization of pharmaceutical products for the treatment of unmet clinical needs, today announced it has signed a licensing agreement with Yeda Research and Development Company Ltd. ("Yeda") to develop hCDR1, a Phase II-ready asset for the treatment of...

2013-07-15 16:23:09

HERZLIYA, Israel, July 15, 2013 /PRNewswire/ -- XTL Biopharmaceuticals, Ltd. (NASDAQ: XTLB) (TASE: XTL) (the "Company"), a clinical-stage biopharmaceutical company focused on the acquisition, development, and commercialization of pharmaceutical products for the treatment of clinical unmet needs, today announced that its ADRs began trading on NASDAQ today, July 15, 2013 under the ticker symbol "XTLB". The Company's ADRs are Level II ADRs, each representing 20 ordinary...

2013-07-10 16:26:03

HERZLIYA, Israel, July 10, 2013 /PRNewswire/ -- XTL Biopharmaceuticals Ltd. (the "Company") (TASE: XTL), (OTC: XTLBY) announced today that NASDAQ approved the Company's listing application and its ADRs will be listed for trading on NASDAQ under the ticker symbol "XTLB". The Company estimates its ADRs will commence trading on NASDAQ in the coming week, because the Company continued its SEC filing even during the period in which it was traded OTC in the United States....

2012-12-05 12:24:49

HERZLIYA, Israel, December 5, 2012 /PRNewswire/ -- XTL Biopharmaceuticals Ltd (TASE: XTL) (OTC: XTLBY) (the "Company", or "XTL"), a biopharmaceutical development company that recently acquired the controlling stake of Proteologics Ltd (TASE: PRTL) announces that Mr. David Grossman, Chief Executive Officer of XTL and Mr. Efri Argaman, were appointed as members of the board of directors of Proteologics. Furthermore, the Board of Directors of Proteologics appointed Mr. Efri Argaman...

2012-11-26 16:25:14

HERZLIYA, Israel, November 26, 2012 /PRNewswire/ -- XTL Biopharmaceuticals Ltd. (TASE: XTL) (OTC: XTLBY) (the "Company"), a biopharmaceutical development company, announced on November 21st that it has acquired 4,620,356 shares, of Proteologics Ltd. (TASE: PRTL) (hereinafter: "the Shares" and "Proteologics", respectively), from Teva Pharmaceutical Industries Ltd. (NYSE: TEVA, TASE: TEVA) (hereinafter: "Teva") in consideration for an amount of approximately NIS 6.5 million, which...

2012-10-04 06:27:24

HERZLIYA, Israel, October 4, 2012 /PRNewswire/ -- XTL Biopharmaceuticals Ltd. (TASE: XTL) (OTC: XTLBY) (the "Company"), a biopharmaceutical development company, announced today that following the announcement from September 24, 2012, its American Depositary Receipts ("ADRs") to ordinary shares ratio has changed today to 1:20 (1 ADR represents 20 ordinary shares). Please note that the ticker Symbol will temporarily change to XTLBD for 20 trading days beginning October 4th, after...

2012-09-24 10:26:25

HERZLIYA, Israel, September 24, 2012 /PRNewswire/ -- XTL Biopharmaceuticals Ltd. ("XTL") today announced that InterCure Ltd. ("InterCure"), which is approximately 45.4% (50.79% on a fully diluted basis) held by XTL, signed a strategic service agreement with a private company ("the Marketing Company") wholly owned by Mr. Shay Ben Yitzhak and Mr. Avner Yassur. Ben Yitzhak and Yassur, who are behind several of the most successful online marketing ventures, are now entering...

2012-09-24 06:28:03

HERZLIYA, Israel, September 24, 2012 /PRNewswire/ -- XTL Biopharmaceuticals Ltd. (TASE: XTL) (OTC: XTLBY) (the "Company"), a biopharmaceutical development company, announced today that it has approved a change in the ratio of its American Depositary Receipts ("ADRs") to ordinary shares in order to facilitate the Company's qualification for listing on the NASDAQ Capital Market. XTL and its advisors believe that following the ADR ratio change, the $4.00 ADR minimum bid...